Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 142Multiple Myeloma 119Prostatic Neoplasms 116Colorectal Neoplasms 75Leukemia, Myeloid, Acute 74Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

tucatinib 1tislelizumab 1disitamab vedotin 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × HER2-positive Gastric Cancer × Clear all
NCT05586061 2025-02-07

RCTS

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
55 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Pieris Pharmaceuticals, Inc.

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡